进行了一项多实验室研究,以建立10种研究药物的肉汤微量稀释MIC质量控制(QC)指南,这些药物先前已证明对流感嗜血杆菌具有显着的活性。流感嗜血杆菌ATCC49247与嗜血杆菌测试培养基的MICQC范围是通过使用多个当代批次的嗜血杆菌测试培养基和国家临床实验室标准委员会推荐的重复测试数量来确定的。根据这些结果,提出了头孢地尼的QC范围(一般为模态MIC+/-一次log2稀释),头孢吡肟,cefetamet,头孢匹罗,头孢替丁,氟罗沙星,替马沙星,克拉霉素,RP59500和曲霉素。最近,美国国家临床实验室标准委员会接受了拟议的克拉霉素和特马沙星的QC指南。
A multilaboratory study was performed to establish broth microdilution MIC quality control (QC)
guidelines for 10 investigational drugs which previously demonstrated significant activity against
Haemophilus influenzae. MIC QC ranges for H. influenzae ATCC 49247 with
Haemophilus test medium were determined by using multiple contemporary lots of
Haemophilus test medium and the National Committee for Clinical Laboratory Standards\' recommended numbers of replicate tests. On the basis of these results, QC ranges (generally modal MIC +/- one log2 dilution) are proposed for cefdinir, cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. The proposed QC
guidelines for clarithromycin and temafloxacin were recently accepted by the National Committee for Clinical Laboratory Standards.